Syndax Pharmaceuticals, Inc. (SNDX) Deep Dive Video
Summary
Syndax offers a de-risked dual-product biotech growth inflection, with asymmetric upside tied to Revuforj frontline expansion and Niktimvo’s potential IPF breakthrough.
View SNDX stock page · Read the SNDX research report
Loading the video player…